Cardiac Function under Antiviral TheRapy

Cardiac Function under Antiviral TheRapy - CoFAcToR Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020975

Enrollment

Registered

2020-08-11

Start date

2019-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B18.2 I50

Interventions

Group 1: Patients are enrolled into the trial, if they are virologically tested positive for HCV. Before the start of therapy we take blood samples and perform an echocardiography. The treatment with

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: HCV positive patients

Exclusion criteria

Exclusion criteria: HBsAg +, clinically manifested coronary heart disease

Design outcomes

Primary

Measure	Time frame
NT-proBNP: before (initial value) and at the end of therapy (follow up - 12 weeks)	—

Secondary

Measure	Time frame
echocardiographic measurements (ejection fraction, LVESV, E/A ratio, ..); laboratory measurements: inflammatory markers (CRP, IL6), transaminases (ALT, AST), gGT, AP	—

Countries

Germany

Contacts

Public ContactDirk Mayer

Klinikum Coburg - REGIOMED

dirk.mayer@klinikum-coburg.de09561-22-33101

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026